Skip to main content
Premium Trial:

Request an Annual Quote

Rob Seitz

Insight Genetics has named Rob Seitz as chief technology officer. As CTO, Seitz will oversee the development and commercialization of Insight's genetic assays for the identification of triple-negative breast cancer using technology licensed out of the Vanderbilt Ingram Cancer Center. Prior to joining Insight, Seitz was senior vice president for technology assessment at Clarient (part of GE Healthcare). He also was co-founder and CEO of Applied Genomics prior to its acquisition by Clarient.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.